-
2
-
-
40749089268
-
Prevalence and causes of iron deficiency anaemia
-
In: Beaumont C, Beris P, Beuzard Y, Brugnara C, editors, Paris: European School of Haematology
-
Hersko C. Prevalence and causes of iron deficiency anaemia. In: Beaumont C, Beris P, Beuzard Y, Brugnara C, editors. Disorders of iron homeostasis, erythrocytes, erythropoiesis. Paris: European School of Haematology; 2006:409-19.
-
(2006)
Disorders of Iron Homeostasis, Erythrocytes, Erythropoiesis
, pp. 409-419
-
-
Hersko, C.1
-
3
-
-
79955045302
-
Clinical use of intravenous iron: Administration, efficacy and safety
-
Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy and safety. Am Soc Hematol Educ Program. 2010:338-47.
-
(2010)
Am Soc Hematol Educ Program
, pp. 338-347
-
-
Auerbach, M.1
Ballard, H.2
-
4
-
-
0040234197
-
Sur les maladies chloropiques et sur un mode de traitement specifique dons ces affecions
-
French
-
Blaud P. [Sur les maladies chloropiques et sur un mode de traitement specifique dons ces affecions]. Rev Med Fr Etrang. 1832;45:357-67. French.
-
(1832)
Rev Med Fr Etrang
, vol.45
, pp. 357-367
-
-
Blaud, P.1
-
5
-
-
79960205047
-
Iron therapy
-
In: Beaumont C, Beris P, Beuzard Y, Brugnara C, editors, Paris: European School of Haematology
-
Brugnara C, Beris P. Iron therapy. In: Beaumont C, Beris P, Beuzard Y, Brugnara C, editors. Disorders of erythropoiesis, erythrocytes and iron metabolism. Paris: European School of Haematology; 2009. p.512-28.
-
(2009)
Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism
, pp. 512-528
-
-
Brugnara, C.1
Beris, P.2
-
7
-
-
43549115913
-
Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease
-
Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103(5):1299-307.
-
(2008)
Am J Gastroenterol
, vol.103
, Issue.5
, pp. 1299-1307
-
-
Gisbert, J.P.1
Gomollón, F.2
-
8
-
-
14544274508
-
Diagnosis and management of iron-deficiency anaemia
-
Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol. 2005;18(2):319-32.
-
(2005)
Best Pract Res Clin Haematol
, vol.18
, Issue.2
, pp. 319-332
-
-
Cook, J.D.1
-
9
-
-
0025786624
-
Tolerability of iron: A comparison of bis-glycino iron II and ferrous sulfate
-
Coplin M, Schuette S, Leichtmann G, Lashner B. Tolerability of iron: a comparison of bis-glycino iron II and ferrous sulfate. Clin Ther. 1991;13(5):606-12.
-
(1991)
Clin Ther
, vol.13
, Issue.5
, pp. 606-612
-
-
Coplin, M.1
Schuette, S.2
Leichtmann, G.3
Lashner, B.4
-
10
-
-
3042845997
-
Safety profiles of Fe2+ and Fe3+ oral preparations in the treatment of iron defiency anemia in children
-
Comment in: Pediatr Hematol Oncol.2005;22(7):645-6; author reply 647-8
-
Kavakli K, Yilmaz D, Cetinkaya B, Balkan C, Sözmen EY, Sagin FG. Safety profiles of Fe2+ and Fe3+ oral preparations in the treatment of iron defiency anemia in children. Pediatr Hematol Oncol. 2004;21(5):403-10. Comment in: Pediatr Hematol Oncol.2005;22(7):645-6; author reply 647-8.
-
(2004)
Pediatr Hematol Oncol
, vol.21
, Issue.5
, pp. 403-410
-
-
Kavakli, K.1
Yilmaz, D.2
Cetinkaya, B.3
Balkan, C.4
Sözmen, E.Y.5
Sagin, F.G.6
-
11
-
-
34447317825
-
Iron (III)-hydroxyde polymaltose complex in iron deficiency anemia
-
Toblli JE, Brinogli R. Iron (III)-hydroxyde polymaltose complex in iron deficiency anemia. Arzneimittelforschung. 2007;57(6A): 431-8.
-
(2007)
Arzneimittelforschung
, vol.57
, Issue.6 A
, pp. 431-438
-
-
Toblli, J.E.1
Brinogli, R.2
-
12
-
-
34447345399
-
Safety and efficacy of iron(III)-hydroxide polymaltose complex. A review of over 25 years experience
-
P. Safety and efficacy of iron(III)-hydroxide polymaltose complex. A review of over 25 years experience. Arzneimittelforschung. 2007;57(6A):439-52.
-
(2007)
Arzneimittelforschung
, vol.57
, Issue.6 A
, pp. 439-452
-
-
-
13
-
-
25444494196
-
Are we giving too much iron? Low-dose iron therapy is effective in octogenarians
-
Comment in: Evid Based Med. 2006;11(3):89; ACP J Club. 2006;144(3):71
-
Rimon E, Kagansky N, Kagansky M, Mechnick L, Mashiah T, Namir M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118(10): 1142-7. Comment in: Evid Based Med. 2006;11(3):89; ACP J Club. 2006;144(3):71.
-
(2005)
Am J Med
, vol.118
, Issue.10
, pp. 1142-1147
-
-
Rimon, E.1
Kagansky, N.2
Kagansky, M.3
Mechnick, L.4
Mashiah, T.5
Namir, M.6
-
14
-
-
77951580026
-
Anemia management in chronic kidney disease: Intravenous iron steps forward
-
Comment on: Am J Hematol. 2010;85 (5):315-9
-
Coyne DW, Auerbach M. Anemia management in chronic kidney disease: Intravenous iron steps forward. Am J Hematol. 2010; 85(5):311-2. Comment on: Am J Hematol. 2010;85 (5):315-9.
-
(2010)
Am J Hematol
, vol.85
, Issue.5
, pp. 311-312
-
-
Coyne, D.W.1
Auerbach, M.2
-
16
-
-
24744435535
-
Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease
-
Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol.2005;40(9):1058-65.
-
(2005)
Scand J Gastroenterol
, vol.40
, Issue.9
, pp. 1058-1065
-
-
Erichsen, K.1
Ulvik, R.J.2
Nysaeter, G.3
Johansen, J.4
Ostborg, J.5
Berstad, A.6
-
17
-
-
0034886891
-
Austrian Inflammatory Bowel Diseases Study Group. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia
-
Comment in: Am J Gastroenterol. 2001;96 (8):2296-8
-
Gasche C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C, Petritsch W; Austrian Inflammatory Bowel Diseases Study Group. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol.2001;96(8):2382-7. Comment in: Am J Gastroenterol. 2001;96 (8):2296-8.
-
(2001)
Am J Gastroenterol
, vol.96
, pp. 2382-2387
-
-
Gasche, C.1
Waldhoer, T.2
Feichtenschlager, T.3
Male, C.4
Mayer, A.5
Mittermaier, C.6
Petritsch, W.7
-
18
-
-
78649713496
-
Tratamento da anemia ferropriva com ferro via parenteral
-
Cançado RD, Lobo C, Friedrich JR. Tratamento da anemia ferropriva com ferro via parenteral. Rev Bras Hematol Hemoter.2010;32(Supl.2):121-8.
-
(2010)
Rev Bras Hematol Hemoter
, vol.32
, Issue.SUPPL.2
, pp. 121-128
-
-
Cançado, R.D.1
Lobo, C.2
Friedrich, J.R.3
-
19
-
-
33644653558
-
Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study
-
Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol.2005;100(1):2503-9.
-
(2005)
Am J Gastroenterol
, vol.100
, Issue.1
, pp. 2503-2509
-
-
Schroder, O.1
Mickisch, O.2
Seidler, U.3
de Weerth, A.4
Dignass, A.U.5
Herfarth, H.6
-
20
-
-
70350648478
-
Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study
-
27
-
Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Granno C, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44(7) 27:838-45.
-
(2009)
Scand J Gastroenterol
, vol.44
, Issue.7
, pp. 838-845
-
-
Lindgren, S.1
Wikman, O.2
Befrits, R.3
Blom, H.4
Eriksson, A.5
Granno, C.6
-
21
-
-
0034323822
-
The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate
-
Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial. 2000;13(6):381-4.
-
(2000)
Semin Dial
, vol.13
, Issue.6
, pp. 381-384
-
-
Fishbane, S.1
Kowalski, E.A.2
-
22
-
-
50449126742
-
Intramuscular iron therapy in iron deficiency anemia
-
Baird IM, Padmore DA. Intramuscular iron therapy in iron deficiency anemia. Lancet. 1954;267(6845):942-6.
-
(1954)
Lancet
, vol.267
, Issue.6845
, pp. 942-946
-
-
Baird, I.M.1
Padmore, D.A.2
-
23
-
-
0029795844
-
The safety of intravenous iron dextran in hemodialysis patients
-
Comment in: Am J Kidney Dis. 2000;35(2):360-1
-
Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996;28(4):529-34. Comment in: Am J Kidney Dis. 2000;35(2):360-1.
-
(1996)
Am J Kidney Dis
, vol.28
, Issue.4
, pp. 529-534
-
-
Fishbane, S.1
Ungureanu, V.D.2
Maesaka, J.K.3
Kaupke, C.J.4
Lim, V.5
Wish, J.6
-
24
-
-
0023120533
-
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial
-
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-8.
-
(1987)
N Engl J Med
, vol.316
, Issue.2
, pp. 73-78
-
-
Eschbach, J.W.1
Egrie, J.C.2
Downing, M.R.3
Browne, J.K.4
Adamson, J.W.5
-
25
-
-
0032572915
-
Erythropoietin for end-stage renal disease
-
Comment on: N Engl J Med. 1998;339(9):578-83. N Engl J Med. 1998;339 (9):584-90
-
Adamson JW, Eschbach JW. Erythropoietin for end-stage renal disease. N Engl J Med. 1998;339(9):625-7. Comment on: N Engl J Med. 1998;339(9):578-83. N Engl J Med. 1998;339 (9):584-90.
-
(1998)
N Engl J Med
, vol.339
, Issue.9
, pp. 625-627
-
-
Adamson, J.W.1
Eschbach, J.W.2
-
26
-
-
31544444964
-
Update on adverse drug events associated with parenteral iron
-
Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21(2):378-82.
-
(2006)
Nephrol Dial Transplant
, vol.21
, Issue.2
, pp. 378-382
-
-
Chertow, G.M.1
Mason, P.D.2
Vaage-Nilsen, O.3
Ahlmén, J.4
-
27
-
-
65949107825
-
Ferric carboxymaltose. A review of its use in iron-deficiency anaemia
-
Lyseng-Williamsom KA, Keating GM. Ferric carboxymaltose. A review of its use in iron-deficiency anaemia. Drugs. 2009;69(6): 739-56.
-
(2009)
Drugs
, vol.69
, Issue.6
, pp. 739-756
-
-
Lyseng-Williamsom, K.A.1
Keating, G.M.2
-
28
-
-
44049104314
-
High-molecular weight iron dextran: A wolf in sheep's clothing?
-
Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy JA, et al. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol. 2008;19(5):833-4.
-
(2008)
J Am Soc Nephrol
, vol.19
, Issue.5
, pp. 833-834
-
-
Rodgers, G.M.1
Auerbach, M.2
Cella, D.3
Chertow, G.M.4
Coyne, D.W.5
Glaspy, J.A.6
-
29
-
-
0033012811
-
Sodium ferric gluconate complex in sucrose; safer intravenous iron therapy than iron dextrans
-
Comment in: Am J Kidney Dis. 1999; 33(3):595-7
-
Faich G, Strobos J. Sodium ferric gluconate complex in sucrose; safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999;33(3):464-70. Comment in: Am J Kidney Dis. 1999; 33(3):595-7.
-
(1999)
Am J Kidney Dis
, vol.33
, Issue.3
, pp. 464-470
-
-
Faich, G.1
Strobos, J.2
-
30
-
-
0036841241
-
Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease
-
Panesar A, Agarwal R. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. Am J Kidney Dis. 2002;40(5):924-31.
-
(2002)
Am J Kidney Dis
, vol.40
, Issue.5
, pp. 924-931
-
-
Panesar, A.1
Agarwal, R.2
-
31
-
-
6444245556
-
Ferlecit Investigators. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and iron dextran-tolerant patients
-
Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG. Ferlecit Investigators. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and iron dextran-tolerant patients. Kidney Int. 2003;63(1):217-24.
-
(2003)
Kidney Int
, vol.63
, Issue.1
, pp. 217-224
-
-
Coyne, D.W.1
Adkinson, N.F.2
Nissenson, A.R.3
Fishbane, S.4
Agarwal, R.5
Eschbach, J.W.6
Michael, B.7
Folkert, V.8
Batlle, D.9
Trout, J.R.10
Dahl, N.11
Myirski, P.12
Strobos, J.13
Warnock, D.G.14
-
32
-
-
4344560350
-
United States Iron Sucrose (Venofer) Clinical Trials Group. Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens
-
Aronoff GR, Bennett WM, Blumenthal S, Charytan C, Pennell JP, Reed J, Rothstein M, Strom J, Wolfe A, Van Wyck D, Yee J; United States Iron Sucrose (Venofer) Clinical Trials Group. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int. 2004;66(3):1193-8.
-
(2004)
Kidney Int
, vol.66
, Issue.3
, pp. 1193-1198
-
-
Aronoff, G.R.1
Bennett, W.M.2
Blumenthal, S.3
Charytan, C.4
Pennell, J.P.5
Reed, J.6
Rothstein, M.7
Strom, J.8
Wolfe, A.9
van Wyck, D.10
Yee, J.11
-
33
-
-
1842579545
-
Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products
-
Chaytan C, Schwenk MH, Al-saloum MM, Spinowitz BS. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract. 2004;96(2):c63-6
-
(2004)
Nephron Clin Pract
, vol.96
, Issue.2
-
-
Chaytan, C.1
Schwenk, M.H.2
Al-Saloum, M.M.3
Spinowitz, B.S.4
-
34
-
-
32844465284
-
For the United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD
-
Comment in: Kidney Int. 2006; 70(6):1188; author reply 1188-9
-
Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S; For the United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846-56. Comment in: Kidney Int. 2006; 70(6):1188; author reply 1188-9.
-
(2005)
Kidney Int
, vol.68
, Issue.6
, pp. 2846-2856
-
-
van Wyck, D.B.1
Roppolo, M.2
Martinez, C.O.3
Mazey, R.M.4
McMurray, S.5
-
35
-
-
39349087499
-
Adverse events associated with intravenous iron infusion (low-molecular weight iron dextran and iron sucrose): A systematic review
-
Critchley J, Dunbar Y. Adverse events associated with intravenous iron infusion (low-molecular weight iron dextran and iron sucrose): a systematic review. Transf Altern Transf Med. 2007;9(1):8-36.
-
(2007)
Transf Altern Transf Med
, vol.9
, Issue.1
, pp. 8-36
-
-
Critchley, J.1
Dunbar, Y.2
-
36
-
-
38049048044
-
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases
-
Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13(12):1545-53.
-
(2007)
Inflamm Bowel Dis
, vol.13
, Issue.12
, pp. 1545-1553
-
-
Gasche, C.1
Berstad, A.2
Befrits, R.3
Beglinger, C.4
Dignass, A.5
Erichsen, K.6
-
37
-
-
40749088084
-
Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion
-
Muñoz M, Breymann C, García-Erce JA, Gómez-Ramírez S, Comin J, Bisbe E. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang. 2008;94(3):172-83.
-
(2008)
Vox Sang
, vol.94
, Issue.3
, pp. 172-183
-
-
Muñoz, M.1
Breymann, C.2
García-Erce, J.A.3
Gómez-Ramírez, S.4
Comin, J.5
Bisbe, E.6
-
38
-
-
43249083205
-
Perioperative anaemia management: Consensus statement on the role of intravenous iron
-
Beris P, Muñoz M, García-Erce JA, Thomas D, Maniatis A, Van der Linden P. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth. 2008; 100(5):599-604.
-
(2008)
Br J Anaesth
, vol.100
, Issue.5
, pp. 599-604
-
-
Beris, P.1
Muñoz, M.2
García-Erce, J.A.3
Thomas, D.4
Maniatis, A.5
Van der Linden, P.6
-
39
-
-
42949084115
-
The role of intravenous iron in anemia management and transfusion avoidance
-
Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion. 2008;48(5):988-1000.
-
(2008)
Transfusion
, vol.48
, Issue.5
, pp. 988-1000
-
-
Auerbach, M.1
Goodnough, L.T.2
Picard, D.3
Maniatis, A.4
-
40
-
-
22844444790
-
Administration of intravenous iron sucrose as a 2-minute push to CKD patients: A prospective evaluation of 2,297 injections
-
MacDougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis. 2005;46(2):283-9.
-
(2005)
Am J Kidney Dis
, vol.46
, Issue.2
, pp. 283-289
-
-
Macdougall, I.C.1
Roche, A.2
-
42
-
-
34247615981
-
Clinical update: Intravenous iron for anaemia
-
Comment in: Lancet. 2007;370(9586):481-2; author reply 482-3. Lancet. 2007;370(9586):482; author reply 482-3
-
Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369(9572):1502-4. Comment in: Lancet. 2007;370(9586):481-2; author reply 482-3. Lancet. 2007;370(9586):482; author reply 482-3.
-
(2007)
Lancet
, vol.369
, Issue.9572
, pp. 1502-1504
-
-
Auerbach, M.1
Ballard, H.2
Glaspy, J.3
-
43
-
-
43549093318
-
A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial
-
Kulnigg S, Stoinov S, Simanenkov, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182-92.
-
(2008)
Am J Gastroenterol
, vol.103
, Issue.5
, pp. 1182-1192
-
-
Kulnigg, S.1
Stoinov, S.2
Simanenkov, D.L.V.3
Karnafel, W.4
Garcia, L.C.5
-
44
-
-
72449156527
-
FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency
-
Comment in: N Engl J Med. 2009;361 (25):2475-7. Ann Intern Med. 2010;152(8):JC4-5
-
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48. Comment in: N Engl J Med. 2009;361 (25):2475-7. Ann Intern Med. 2010;152(8):JC4-5.
-
(2009)
N Engl J Med
, vol.361
, Issue.25
, pp. 2436-2448
-
-
Anker, S.D.1
Comin, C.J.2
Filippatos, G.3
Willenheimer, R.4
Dickstein, K.5
Drexler, H.6
Lüscher, T.F.7
Bart, B.8
Banasiak, W.9
Niegowska, J.10
Kirwan, B.A.11
Mori, C.12
von Eisenhart Rothe, B.13
Pocock, S.J.14
Poole-Wilson, P.A.15
Ponikowski, P.16
-
45
-
-
71849101678
-
Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized controlled trial
-
Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized controlled trial. Transfusion. 2009;49(12):2719-28.
-
(2009)
Transfusion
, vol.49
, Issue.12
, pp. 2719-2728
-
-
van Wyck, D.B.1
Mangione, A.2
Morrison, J.3
Hadley, P.E.4
Jehle, J.A.5
Goodnough, L.T.6
-
46
-
-
77954797927
-
The safety and efficacy of intravenous iron carboxymaltose in anaemic patients underoing haemodialysis: A multi-centre, open-label, clinical study
-
Covic A, Mircescu G. The safety and efficacy of intravenous iron carboxymaltose in anaemic patients underoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Trans. 2010; 25(8):2722-30.
-
(2010)
Nephrol Dial Trans
, vol.25
, Issue.8
, pp. 2722-2730
-
-
Covic, A.1
Mircescu, G.2
-
47
-
-
84856364344
-
Iron supplementation: Focus on ferric carboxymaltose [Internet]
-
Available from
-
Macdougall L, Chappeli J, Chai MO. Iron supplementation: focus on ferric carboxymaltose [Internet]. Hosp Pharm Eur. 2010; (51):27-9. Available from: http://www.hospitalpharmacyeurope.com/defaul.asp?title=Iron_supplementation%3A_ocus_on_ferric_carboxymaltose&page=article.display&article.id=22670
-
(2010)
Hosp Pharm Eur
, vol.51
, pp. 27-29
-
-
Macdougall, L.1
Chappeli, J.2
Chai, M.O.3
-
48
-
-
79960617268
-
A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications
-
Jahn MR, Andreasen HB, Futterer SA, Nawroth T, Schunemann V, Kolb U, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78(3):480-91.
-
(2011)
Eur J Pharm Biopharm
, vol.78
, Issue.3
, pp. 480-491
-
-
Jahn, M.R.1
Andreasen, H.B.2
Futterer, S.A.3
Nawroth, T.4
Schunemann, V.5
Kolb, U.6
-
49
-
-
54149119169
-
Safety of ferumoxytol in patients with anemia and CKD
-
Comment in: Am J Kidney Dis. 2008; 52(5):826-9
-
Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52(5):907-15. Comment in: Am J Kidney Dis. 2008; 52(5):826-9
-
(2008)
Am J Kidney Dis
, vol.52
, Issue.5
, pp. 907-915
-
-
Singh, A.1
Patel, T.2
Hertel, J.3
Bernardo, M.4
Kausz, A.5
Brenner, L.6
-
50
-
-
66849104249
-
Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients
-
Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4(2): 386-93.
-
(2009)
Clin J Am Soc Nephrol
, vol.4
, Issue.2
, pp. 386-393
-
-
Provenzano, R.1
Schiller, B.2
Rao, M.3
Coyne, D.4
Brenner, L.5
Pereira, B.J.6
-
51
-
-
77951619720
-
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease
-
Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010;85(5):315-9.
-
(2010)
Am J Hematol
, vol.85
, Issue.5
, pp. 315-319
-
-
Lu, M.1
Cohen, M.H.2
Rieves, D.3
Pazdur, R.4
-
52
-
-
84856345068
-
Benefits from ambulatory administration of intravenous iron up to one gram per session
-
Barcelona
-
García-Erce JA, Soria B, Cuenca J, Rubio F, Muñoz M. Benefits from ambulatory administration of intravenous iron up to one gram per session. LI Annual Meeting of the Spanish Association of Haematology and Haemotherapy, Barcelona; 2009.
-
(2009)
LI Annual Meeting of the Spanish Association of Haematology and Haemotherapy
-
-
García-Erce, J.A.1
Soria, B.2
Cuenca, J.3
Rubio, F.4
Muñoz, M.5
-
53
-
-
66949124302
-
Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment
-
Kulnigg S, Teischinger L, Dejaco C, Waldhör T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104(6):1460-7.
-
(2009)
Am J Gastroenterol
, vol.104
, Issue.6
, pp. 1460-1467
-
-
Kulnigg, S.1
Teischinger, L.2
Dejaco, C.3
Waldhör, T.4
Gasche, C.5
-
54
-
-
78049527707
-
Efficacy and safety of standardised ferric carboxymaltose doses vs. individually calculated iron sucrose doses for IBDassociated iron deficiency anemia: A multicentre, randomised controlled trial
-
Evstatiev, R. Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. Efficacy and safety of standardised ferric carboxymaltose doses vs. individually calculated iron sucrose doses for IBDassociated iron deficiency anemia: a multicentre, randomised controlled trial. Presented at the 18th United European Gastroenterology Week, Barcelona, 2010: P0420.
-
(2010)
Presented at the 18th United European Gastroenterology Week Barcelona
-
-
Evstatiev, R.1
Marteau, P.2
Iqbal, T.3
Khalif, I.L.4
Stein, J.5
Bokemeyer, B.6
-
55
-
-
0038119551
-
Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin
-
Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int. 2003;64(2):572-8.
-
(2003)
Kidney Int
, vol.64
, Issue.2
, pp. 572-578
-
-
Weiss, G.1
Meusburger, E.2
Radacher, G.3
Garimorth, K.4
Neyer, U.5
Mayer, G.6
-
56
-
-
84856323168
-
-
editors, 4th ed. Bremen: Uni-Med Verlag
-
Crichton RR, Danielson BG, Geisser P, editors. Iron therapy, with special emphasis on intravenous administration. 4th ed. Bremen: Uni-Med Verlag; 2008. p.71.
-
(2008)
Iron Therapy, with Special Emphasis on Intravenous Administration
, pp. 71
-
-
Crichton, R.R.1
Danielson, B.G.2
Geisser, P.3
-
57
-
-
19044389821
-
Iron and immunity: A double-edged sword
-
Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest. 2002;32 (Suppl 1):70-8.
-
(2002)
Eur J Clin Invest
, vol.32
, Issue.SUPPL. 1
, pp. 70-78
-
-
Weiss, G.1
-
58
-
-
0032940723
-
Iron status and iron supplementation in peritoneal dialysis patients
-
Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl. 1999;69:S71-8.
-
(1999)
Kidney Int Suppl
, vol.69
-
-
Vychytil, A.1
Haag-Weber, M.2
-
59
-
-
79953087440
-
Posibilidades de tratamiento de la anemia perioperatoria en cirugía ortopédica y traumatología
-
García-Erce JA, Cuenca J, Gómez-Ramírez S, Villar I, Herrera A, Muñoz M. Posibilidades de tratamiento de la anemia perioperatoria en cirugía ortopédica y traumatología. Anemia. 2009;2:17-27.
-
(2009)
Anemia
, vol.2
, pp. 17-27
-
-
García-Erce, J.A.1
Cuenca, J.2
Gómez-Ramírez, S.3
Villar, I.4
Herrera, A.5
Muñoz, M.6
-
60
-
-
0345708218
-
Iron overload and its association with cancer risk in humans: Evidence for iron as a carcinogenic metal
-
Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res. 2003;533(1-2):153-71.
-
(2003)
Mutat Res
, vol.533
, Issue.1-2
, pp. 153-171
-
-
Huang, X.1
-
61
-
-
9644294211
-
Labile iron: Manifestations and clinical implications
-
Van Wyck DB. Labile iron: manifestations and clinical implications. J Am Soc Nephrol. 2004;15 (Suppl 2):S107-11.
-
(2004)
J Am Soc Nephrol
, vol.15
, Issue.SUPPL. 2
-
-
van Wyck, D.B.1
-
62
-
-
0030040395
-
The role of iron in cancer
-
Weinberg ED. The role of iron in cancer. Eur J Cancer Prev. 1996;5(1):19-36
-
(1996)
Eur J Cancer Prev
, vol.5
, Issue.1
, pp. 19-36
-
-
Weinberg, E.D.1
-
63
-
-
67349137868
-
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents
-
Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2009; 1790(7):702-17
-
(2009)
Biochim Biophys Acta
, vol.1790
, Issue.7
, pp. 702-717
-
-
Richardson, D.R.1
Kalinowski, D.S.2
Lau, S.3
Jansson, P.J.4
Lovejoy, D.B.5
-
64
-
-
7044222320
-
Iron, hemochromatosis, and hepatocellular carcinoma
-
Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S79-86.
-
(2004)
Gastroenterology
, vol.127
, Issue.5 SUPPL. 1
-
-
Kowdley, K.V.1
-
65
-
-
0034725897
-
Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation
-
Barton JC, Barton EH, Bertoli LF, Gothard CH, Sherrer JS. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000:109(1):27-32.
-
(2000)
Am J Med
, vol.109
, Issue.1
, pp. 27-32
-
-
Barton, J.C.1
Barton, E.H.2
Bertoli, L.F.3
Gothard, C.H.4
Sherrer, J.S.5
-
66
-
-
0032033665
-
Value of methylprednisolone in prevention of the arthralgias-myalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial
-
Auerbach M, Chaudhry M, Goldman H, Ballard H. Value of methylprednisolone in prevention of the arthralgias-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med. 1998;131 (3):257-60.
-
(1998)
J Lab Clin Med
, vol.131
, Issue.3
, pp. 257-260
-
-
Auerbach, M.1
Chaudhry, M.2
Goldman, H.3
Ballard, H.4
-
67
-
-
77956481295
-
Use of parenteral iron products and serious anaphylactic-type reactions
-
Comment in: Am J Hematol. 2010;85(9):643-4
-
Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010;85(9):650-4. Comment in: Am J Hematol. 2010;85(9):643-4
-
(2010)
Am J Hematol
, vol.85
, Issue.9
, pp. 650-654
-
-
Wysowski, D.K.1
Swartz, L.2
Borders-Hemphill, B.V.3
Goulding, M.R.4
Dormitzer, C.5
-
68
-
-
34248592639
-
Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
-
Sav T, Tokgoz B, Sipahioglu MH, Deveci M, Sari I, Oymak O, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007;29 (4):423-6.
-
(2007)
Ren Fail
, vol.29
, Issue.4
, pp. 423-426
-
-
Sav, T.1
Tokgoz, B.2
Sipahioglu, M.H.3
Deveci, M.4
Sari, I.5
Oymak, O.6
|